Preliminary experiments showed that BKM120 (a pan-PI3K inhibitor that decreases glucose consumption by reducing the release of active aldolase from actin cytoskeleton) and CB-839 (a reversible non-competitive allosteric GLS inhibitor) are active on both A549 and HCT116 cancer cell lines, eliciting the expected biochemical effect, i.e., a decrease in aldolase activity and intracellular glutamate concentration (Figure S1B and C). This evidence concerns the gene GLS and cancer.